NCT03953235: A trial that was reported late by Gritstone Bio, Inc.
This trial has reported, although it was 292 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT03953235 |
|---|---|
| Title | A Phase 1/2 Study of GRT-C903/GRT-R904, a Vaccine Targeting Shared Neoantigens, in Combination With Immune Checkpoint Blockade for Patients With Advanced Solid Tumors |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | July 18, 2019 |
| Completion date | March 10, 2023 |
| Required reporting date | March 9, 2024, midnight |
| Actual reporting date | Dec. 27, 2024 |
| Date last checked at ClinicalTrials.gov | June 3, 2026 |
| Days late | 292 |